Société Curis, Inc. Nasdaq
Actions
US2312691015
Recherche biotechnologique et médicale
Métier
Ventes par activité
USD en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
Discovery and Development of Innovative Drug
100,0
%
| 10 | 100,0 % | 10 | 100,0 % | -1,37 % |
Ventes par région
USD en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 10 | 100,0 % | 10 | 100,0 % | -1,37 % |
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
James Dentzer
CEO | Chief Executive Officer | 57 | 29/03/16 |
Diantha Duvall
DFI | Director of Finance/CFO | 52 | 26/07/22 |
Chief Tech/Sci/R&D Officer | - | 03/01/22 | |
Chief Tech/Sci/R&D Officer | - | 13/08/19 | |
Chief Tech/Sci/R&D Officer | 61 | 01/09/11 | |
Mark W. Noel
CTO | Chief Tech/Sci/R&D Officer | 65 | 01/03/01 |
Rachel Blasbalg
HRO | Human Resources Officer | - | 01/01/04 |
Dora Ferrari
PRN | Corporate Officer/Principal | - | 03/01/21 |
Nancy Soohoo
LAW | General Counsel | - | 01/01/03 |
Jonathan Zung
PRN | Corporate Officer/Principal | 59 | 01/05/23 |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Director/Board Member | 71 | 01/11/03 | |
Chairman | 82 | 14/02/00 | |
James Dentzer
CEO | Chief Executive Officer | 57 | 29/03/16 |
Marc Rubin
BRD | Director/Board Member | 69 | 03/06/10 |
Chief Tech/Sci/R&D Officer | 61 | 01/09/11 | |
Anne Borgman
BRD | Director/Board Member | 56 | - |
John Hohneker
BRD | Director/Board Member | 64 | 02/12/21 |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 1 | 5 894 085 | 5 883 204 ( 99,82 %) | 0 | 99,82 % |
Coordonnées société
Secteur
Varia. 1 janv. | Capi. | |
---|---|---|
+1,51 % | 42,75 Md | |
+49,22 % | 41,61 Md | |
+8,57 % | 41,34 Md | |
-12,36 % | 26,59 Md | |
+8,92 % | 25,49 Md | |
-25,13 % | 18,12 Md | |
+29,17 % | 12,24 Md | |
-3,12 % | 11,76 Md | |
+6,35 % | 11 Md |